Physician profile
Ray Scott Daugherty
NPI 1144544164
$9,858.57
in general payments reported to CMS, 2019-2025
45 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 79% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $215 · 2021: $295 · 2022: $466 · 2023: $1,274 · 2024: $5,717 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402 · Education: $4,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.34 |
| Education | $4,164.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,345.02 | 2020-2024 | |
| Abbvie INC. | $1,077.44 | 2022-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $842.46 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $619.76 | 2022-2025 | Stelara, Tremfya, Remicade |
| Lilly USA, LLC | $355.85 | 2023-2025 | Omvoh |
| Ethicon US, LLC | $262.16 | 2019-2025 | Certus 140, Proximate, Echelon; Endopath |
| Tas Medical, INC. | $218.48 | 2024 | |
| Daiichi Sankyo INC. | $193.38 | 2022-2023 | Injectafer |
| Davol INC. | $166.43 | 2023-2025 | Arista Ah Flexitip, Phasix Mesh, Channel Drain |
| Baxter Healthcare | $144.60 | 2020-2023 | Tisseel |
| Pacira Pharmaceuticals Incorporated | $120.90 | 2019-2025 | Exparel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.54 | 2019-2020 | |
| Organon LLC | $99.35 | 2023-2025 | Hadlima |
| Kowa Pharmaceuticals America, INC. | $92.56 | 2022-2023 | Seglentis |
| Biocon Biologics INC | $85.47 | 2024-2025 | Hulio, Yesintek |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $81.26 | 2019-2024 | Suflave, Sutab |
| Stryker Corporation | $73.17 | 2023 | Spy-Phi System, 1688 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.55 | 2023 | Cyltezo |
| Aroa Biosurgery Incorporated | $66.43 | 2022-2023 | |
| Becton, Dickinson and Company | $64.51 | 2023-2024 | Phasix Mesh |
| Vertex Pharmaceuticals Incorporated | $60.26 | 2025 | |
| Pfizer INC. | $56.44 | 2023 | |
| Histosonics, INC. | $53.89 | 2025 | |
| Ferring Pharmaceuticals INC. | $43.51 | 2019 | |
| Alcresta Therapeutics, INC. | $39.23 | 2023 | Relizorb |
| Fresenius Kabi USA, LLC | $39.17 | 2023 | Idacio |
| Dilon Technologies, INC. | $38.90 | 2025 | Hemoblast Bellows |
| Merck Sharp & Dohme LLC | $37.35 | 2019 | |
| Solventum Corporation | $36.77 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C. Veraflo |
| Celltrion USA INC. | $35.16 | 2023-2025 | Vegzelma, Yuflyma |
| Tela Bio, INC. | $33.83 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Innovation Technologies INC | $30.76 | 2024 | Irrisept |
| Medtronic, INC. | $29.62 | 2025 | Endoflip |
| Convatec INC. | $28.03 | 2019 | |
| Cook Biotech Incorporated | $23.25 | 2023 | Fortify Flowable |
| La Jolla Pharmaceutical Company | $21.12 | 2024 | Xerava |
| Aimmune Therapeutics, INC. | $20.60 | 2025 | Zenpep |
| Acacia Pharma INC | $17.91 | 2021 | |
| Shire North American Group INC | $17.88 | 2019 | |
| Novo Nordisk INC | $17.79 | 2023 | Wegovy |
| Pharmacosmos Therapeutics INC. | $17.13 | 2024 | Monoferric |
| Hollister Incorporated | $16.16 | 2025 | Hollister |
| Edwards Lifesciences Corporation | $14.92 | 2021 | |
| Sanara Medtech INC. | $14.84 | 2024 | Celleraterx |
| Coopersurgical, INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.